The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
Open accessAbstract
OBJECTIVE: Ipilimumab is a fully human MAB against cytotoxic T-lymphocyte antigen 4 (CTLA4). CTLA4 negatively regulates immune cell activation. In patients with metastatic melanoma, ipilimumab increases survival time and induces complete remission in some patients. However, immune-related adverse events including endocrinopathies have been reported. Bevacizumab, an angiogenesis inhibitor, has been used in combination with ipilimumab in patients with advanced melanoma. PATIENTS AND METHODS: In this study, we report three patients who received ipilimumab alone or combined with bevacizumab therapy and developed thyroiditis, and the first report of euthyroid Graves' ophthalmopathy. RESULTS: Case 1 is a 51-year-old female who presented with severe eye pain, proptosis, and periorbital edema. Laboratory results revealed normal TSH, elevated thyroid antibodies but low titer of anti-TSH receptor antibody. Imaging was consistent with Graves' ophthalmopathy. Cases 2 and 3 were referred for hyperthyroidism, and workup revealed thyroiditis. These three cases suggest that patients with advanced melanoma treated with ipilimumab +/- bevacizumab may be susceptible to a variety of thyroid disorders. CONCLUSIONS: Anti-CTLA4 therapy has shown promising results in treating advanced malignancy such as melanoma and renal carcinoma. A number of endocrinopathies, including thyroid disorders, may develop during ipilimumab therapy. The association of bevacizumab with endocrinopathies is not clear, although a few reports suggest a link to hypothyroidism. All patients on ipilimumab and/or bevacizumab therapy should be monitored for signs or symptoms of thyroiditis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To the best of our knowledge at the time of writing, only nine cases of ICPi-induced Graves’ hyperthyroidism and seven cases of induced Graves’ orbitopathy have been described in the literature, associated with anti-PD-1 or anti-CTLA-4 treatment or their combination (Table 3), with only one patient presenting with both thyrotoxicosis and orbitopathy [19,29,30,31,35,36,37,38,39,40,41,42,43,44].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the literature, initially only induced Graves’ orbitopathy (GO) without thyrotoxicosis were described in patients undergoing Ipilimumab (anti-CTLA-4) treatment [29,30,31].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [30]
In the citing paper
“has been increasing in recognition and diagnosis.66”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [66]
In the citing paper
“whereas reports of cases on CTLA-4 monotherapy are very rare”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [66]
In the citing paper
“though diabetes has developed several months after ICI cessation 66”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [66]
In the citing paper
“Most patients develop ICI-DM while on therapy”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [66]
In the citing paper
“Approximately 97% of all reported ICI-DM cases have arisen with anti-PD-1/PD-L1 or combination treated patients”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [66]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Bahn, R. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0905750 · Cited by 1,552
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Chambers, C. A., Kuhns, M. S., Egen, J. G., & Allison, J. P. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.565 · Cited by 1,000
Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Kamba, T., Tam, B. Y. Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso, M. R., Norberg, S. M., O’Brien, S., Davis, R. B., Gowen, L. C., et al. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00133.2005 · Cited by 788
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624
Weber, J. S., Thompson, J. A., Hamid, O., Minor, D. R., Amin, A., Ron, I. G., Ridolfi, R., Assi, H. I., Maraveyas, A., Berman, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1024 · Cited by 566
Sanderson, K. M., Scotland, R., Lee, P. P., Liu, D., Groshen, S. G., Snively, J., Sian, S., Nichol, G. M., Davis, T. A., Keler, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.128 · Cited by 433
Cited by
Sorted by citations
Items 101–177 of 177
The side effects of immune checkpoint inhibitor therapy on the endocrine system
Goyal, I., Pandey, M. R., Sharma, R. K., Chaudhuri, A., & Dandona, P. (2021) · International Journal of Microbiology Research · doi:10.4103/ijmr.ijmr_313_19 · Cited by 18
Winges, K. M., & Gordon, L. K. (2022) · Frontiers in Ophthalmology · doi:10.3389/fopht.2022.1044904 · Cited by 17
Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)
Corsello, S. M., Salvatori, R., Barnabei, A., Vecchis, L. D., Marchetti, P., & Torino, F. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2213-y · Cited by 17
Immune-related endocrine disorders in novel immune checkpoint inhibition therapy
Min, L. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.10.002 · Cited by 16
Self-citationRhea, L. P., Yoon, J. W., & Jang, S. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00442 · Cited by 16
Anti-CTLA4 Antibody Therapy Related Complications on FDG PET/CT
Koo, P. J., Klingensmith, W. C., Lewis, K. D., Bagrosky, B. M., & Gonzalez, R. C. (2013) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e318292a775 · Cited by 15
Ipilimumab-Induced Immunomediated Adverse Events
Gilardi, L., Colandrea, M., Vassallo, S., Travaini, L. L., & Paganelli, G. (2013) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e31828da691 · Cited by 15
Diamanti‐Kandarakis, E., Duntas, L. H., Kanakis, G., Kandaraki, E., Karavitaki, N., Kassi, E. N., Livadas, S., Mastorakos, G. P., Migdalis, I. N., Miras, A. D., et al. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0154 · Cited by 15
Gridelli, C. (2016) · Journal of Endocrinology and Diabetes · doi:10.15226/2374-6890/3/1/00143 · Cited by 15
Cancer Therapy with Checkpoint Inhibitors: Establishing a Role for Ophthalmology
Davis, M. E., & Francis, J. H. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.08.003 · Cited by 15
Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma
Lu, J. E., Chang, J. R., Berry, J. L., In, G. K., & Zhang-Nunes, S. (2020) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000308 · Cited by 14
Sohrab, M. A., Desai, R. U., Chambers, C. B., & Lissner, G. S. (2013) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0b013e3182895795 · Cited by 14
Zhu, L., Cheung, Y.-M. M., Chiang, C. Y., Gallagher, E. J., Hamnvik, O. R., Mammen, J. S., Quandt, Z., Jones, R., McDunn, J., Al-Bahadili, H., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011865 · Cited by 13
Immunological Processes in the Orbit and Indications for Current and Potential Drug Targets
Cieplińska, K., Niedziela, E., & Kowalska, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010072 · Cited by 13
Harnessing Immune Checkpoints for Cancer Therapy
Vinay, D. S., & Kwon, B. S. (2018) · Immunotherapy · doi:10.2217/imt-2017-0168 · Cited by 14
Endocrine Adverse Events Related with Immune Checkpoint Inhibitors: An Update for Clinicians
Deligiorgi, M. V., Panayiotidis, M. I., & Trafalis, D. T. (2020) · Immunotherapy · doi:10.2217/imt-2019-0132 · Cited by 13
Hou, Y., Wang, D., Hu, J., Tian, R., Wang, W., Su, Q., Li, H., & Wang, Y. (2021) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2021.1890133 · Cited by 12
Ipilimumab-related orbitopathy: a case report
Jebaraj, A. P., Etheridge, T. J., Winegar, B. A., & Marx, D. P. (2022) · Orbit · doi:10.1080/01676830.2022.2074049 · Cited by 11
Immune checkpoint inhibitor-related thyroid dysfunction
Illouz, F., Briet, C., & Rodien, P. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2023.03.005 · Cited by 11
Long-term and late treatment consequences: endocrine and metabolic effects
Han, T. S., & Gleeson, H. K. (2017) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000289 · Cited by 11
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Mößner, R., Ugurel, S., Zimmer, L., Gutzmer, R., & (ADO), F. D. K. „. N. D. A. D. O. (2016) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13047_g · Cited by 11
Nardin, C., Borot, S., Beaudoin, M. A., Cattin, F., Puzenat, E., Gauthier, A.-S., Schillo, F., Borg, C., & Aubin, F. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0659-9 · Cited by 10
Iglesias, P., Soria, A., & Díez, J. J. (2015) · Medicina Clínica · doi:10.1016/j.medcli.2015.02.010 · Cited by 10
de Filette, J. M. K., André, S., Mey, L. D., Aspeslagh, S., Karmali, R., der Auwera, B. J. R. V., & Bravenboer, B. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01190-5 · Cited by 9
Douglas, V. P., Douglas, K. A. A., & Cestari, D. M. (2019) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000608 · Cited by 9
Les dysthyroïdies sous immunothérapie anti-cancéreuse
Anceau, C. C., Abeillon, J., Maillet, D., Borson‐Chazot, F., & Disse, E. (2019) · Bulletin du Cancer · doi:10.1016/j.bulcan.2019.10.005 · Cited by 9
Chau, C. Y. C., Shih, K. C., Chow, L. L. W., & Lee, V. H.-F. (2020) · Ophthalmology and Therapy · doi:10.1007/s40123-020-00317-y · Cited by 9
Okamura, K., Bandai, S., Fujikawa, M., Sato, K., & Kitazono, T. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0016 · Cited by 8
A case of thyroiditis during natalizumab therapy for multiple sclerosis
Oddo, S., Laroni, A., Uccelli, A., & Giusti, M. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03347466 · Cited by 8
Becquart, C., Ryckewaert, G., Desmedt, E., Defebvre, L., Rhun, É. L., & Mortier, L. (2013) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2013.01.424 · Cited by 7
Furtado, V. F., Melamud, K., Hassan, K., Rohatgi, S., & Buch, K. A. (2020) · Clinical Imaging · doi:10.1016/j.clinimag.2020.02.006 · Cited by 7
Zhang, Y., Garofano, F., Wu, X., Schmid, M. C., Krawitz, P. M., Essler, M., & Schmidt‐Wolf, I. G. H. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00952-z · Cited by 6
Madala, S., Parikh, A. O., Hong, K., & Burnstine, M. A. (2025) · Frontiers in Ophthalmology · doi:10.3389/fopht.2025.1574643 · Cited by 5
Thyroïdites : où en est-on en 2019 ?
Rouland, A., Buffier, P., Petit, J.-M., Vergès, B. L., & Bouillet, B. (2020) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2020.02.003 · Cited by 5
Clínica, G. D. T. D. S. B. D. O. (2017) · Brazilian Journal of Oncology · doi:10.1055/s-0044-1792178 · Cited by 5
Immune checkpoint inhibitors associated thyroiditis: mechanisms and clinical outcomes
Hammerstad, S. S., Lee, H. J., Tomer, Y., & Stefan–Lifshitz, M. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02608-2 · Cited by 4
Drugs and Other Substances Interfering with Thyroid Function
Montanelli, L., Benvenga, S., Hegedűs, L. D., Vitti, P., Latrofa, F., & Duntas, L. H. (2018) · Endocrinology · doi:10.1007/978-3-319-29195-6_27-1 · Cited by 4
Autoimmune endocrinopathies induced by immunomodulating antibodies in the treatment of cancer
Iglesias, P., Soria, A., & Díez, J. J. (2015) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.02.022 · Cited by 4
Lenalidomide-Associated Thyroid-Related Eyelid Retraction
Slean, G. R., & Silkiss, R. Z. (2017) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000001012 · Cited by 4
Nivolumab-induced thyroid dysfunction in patients with lung cancer
Ramos-Levi, A. M., Rogado, J., Sánchez-Torres, J. M., Colomer, R., & Marazuela, M. (2019) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.12.001 · Cited by 4
Thyroid Function Abnormalities in Patients Receiving Anticancer Agents
Torino, F., Barnabei, A., Baldelli, R., & Appetecchi, M. (2012) · InTech eBooks · doi:10.5772/50375 · Cited by 4
Krecké, N., Zimmer, A. H., Friesenhahn‐Ochs, B., Müller, F. M., VOGT, T. M., & Pföhler, C. (2016) · Dermato-Endocrinology · doi:10.1080/19381980.2016.1199307 · Cited by 4
Lesions in endocrine glands as a complication of immunotherapy in the practice of oncologist
Nuralieva, N. F., Troshina, E. A., & Mel'nichenko, G. A. (2019) · Clinical and experimental thyroidology · doi:10.14341/ket9875 · Cited by 4
Pan, M., Zhou, X., & Wu, Y. F. (2025) · Diagnostics · doi:10.3390/diagnostics15212764 · Cited by 3
Nassar, A., Rivera, N., Méndez, J. M. M., & Martinez, A. (2020) · Journal of Neurology & Stroke · doi:10.15406/jnsk.2020.10.00434 · Cited by 3
Antibodies to Stimulate Host Immunity
Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00019-1 · Cited by 3
Ipilimumab-Induced Hypophysitis May Not Affect All Pituitary Cell Lines: A Case Report
Kotwal, A., Rao, S. N., & Haas, R. A. (2015) · Journal of Endocrinology and Metabolism · doi:10.14740/jem287w · Cited by 3
Hidaka, R., Hiromatsu, Y., Tatsumoto, N., Fukuyama, T., SAGARA, Y., Uchida, A., TAMAI, H., Tojikubo, M., Akehi, Y., Kawasaki, E., et al. (2024) · The Kurume Medical Journal · doi:10.2739/kurumemedj.ms7134008 · Cited by 2
Souri, Z., & Pakdel, F. (2024) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v19i3.15047 · Cited by 2
Sakai, A., Tagami, M., Misawa, N., Haruna, Y., Tomita, M., & Honda, S. (2024) · Frontiers in Ophthalmology · doi:10.3389/fopht.2024.1491053 · Cited by 2
Cieplińska, K., Niedziela, E., Rdzanek, A. K., Słuszniak, A., Chrapek, M., Pałyga, I., & Kowalska, A. (2025) · Cytokine · doi:10.1016/j.cyto.2025.156862 · Cited by 2
Orbital Disease in Neuro-Ophthalmology
Shindler, K. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-34044-1.00018-3 · Cited by 2
Fraunfelder, F. “. T., & Fraunfelder, F. “. W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-65375-6.00015-3 · Cited by 2
Wémeau, J.-L., BERTAGNA, X. Y., & Boîtard, C. (2018) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30188-8 · Cited by 1
Medication-associated thyroid eye disease: a review
Ang, T., Almater, A. I., & Selva, D. N. (2026) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-025-07089-w · Cited by 1
Endocrine Toxicities of Immunotherapy
Pandey, M. R., Goyal, I., & Ernstoff, M. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-67241-2.00018-5 · Cited by 1
Thyroid effects and anticancer treatment
Nozières, C., Damatte-Fauchery, C., & Borson‐Chazot, F. (2011) · Annales d Endocrinologie · doi:10.1016/j.ando.2011.04.002 · Cited by 1
Nebenwirkungen nach Immuntherapie in der Hämatologie und Onkologie
Buchtele, N., & Schellongowski, P. (2019) · Wiener klinische Wochenschrift Education · doi:10.1007/s11812-019-00096-y · Cited by 1
Varghese, J. M., & Best, C. J. (2022) · Springer eBooks · doi:10.1007/978-3-031-00241-0_4 · Cited by 1
Rosenquist, K. J., & Kaiser, U. B. (2013) · Wiley eBooks · doi:10.1002/9781118559406.ch12 · Cited by 1
Rituximab therapy in steroid-resistant severe hypothyroid Grave′s ophthalmopathy
Garg, M., Pandit, A., Gundgurthi, A., Kharb, S., & Brar, K. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.109669
PATOLOGIAS INDUZIDAS POR DROGAS: AUTOIMUNIDADE, COMPROMETIMENTO PULMONAR E DO MOVIMENTO
Anghebem-Oliveira, M. I. (2014) · Revista Eletrônica de Farmácia · doi:10.5216/ref.v11i3.27788
Low Thyroid-Stimulating Hormone: What Is Next?
Beer, K. A. (2016) · Physician Assistant Clinics · doi:10.1016/j.cpha.2016.08.013
Management and Supportive Care of Patients Undergoing Immunotherapy
Rapoport, B. L., & Eeden, R. I. V. (2017) · InTech eBooks · doi:10.5772/67372
Onkologische Immuntherapie und mögliche endokrine Nebenwirkungen bei Frauen
Zdanytė, K., & Kiesel, L. (2019) · Gynäkologische Endokrinologie · doi:10.1007/s10304-019-0255-x
Juarez, R., Taliaferro, A. S., & Behr, S. C. (2020) · Current Radiology Reports · doi:10.1007/s40134-020-00369-9
Endokrynologiczne powikłania nowych terapii przeciwnowotworowych
Miner, M., Elbaum, M., Jawiarczyk-Przybyłowska, A., & Kubicka, E. (2021) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/01.3001.0014.8121
Endocrinopathies Associated With Immune Checkpoint Inhibitors
Girotra, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-76097-3.00024-7
Hui, L., Junhua, Z., Xiaoyu, G., Wang, L., & Qiao, X. (2022) · Research Square · doi:10.21203/rs.3.rs-1052999/v1
Bower, M. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.725788239.793561104
Endocrine Consequences Following Immune Checkpoint Inhibitors Therapy
Lavrentaki, A., & Ntali, G. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_172-1
Graves’ Disease After Prolonged Immune Checkpoint Inhibitor Therapy
Patel, J. R., & Best, C. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-83533-9_7
Immunotherapy in the Treatment of Melanoma
Katsouda, A., Rallis, T., Gogakos, A. S., Theocharidis, V., Kanteres, T., Tzinevi, M., Passos, I. D., & Mironidou‐Tzouveleki, M. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1011805
Endocrine Consequences Following Immune Checkpoint Inhibitors Therapy
Lavrentaki, A., & Ntali, G. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_172
Nakassa, A. C. I., Facchin, M. P. S., Carregaro, V., & Cruz, A. A. V. E. (2026) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000003184
Neuro-Ophthalmic Complications of Immune Checkpoint Inhibitors
García, C. R., & Al-Zubidi, N. S. (2026) · Neurologic Clinics · doi:10.1016/j.ncl.2025.11.005
Guo, H., & Li, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1762151
Metadata
- Authors
- Min, L., Vaidya, A., & Becker, C.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Becker, Carolyn
- ORCID
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-02
- Volume
- 164
- Issue
- 2
- Pages
- 303-307
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- PMC
- PMC4080629
- OpenAlex
- W2127446775
- Cited by
- 179
- References
- 22
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 5 · 2023: 6 · 2022: 12 · 2021: 8 · 2020: 17 · 2019: 17 · 2018: 24 · 2017: 21 · 2016: 14 · 2015: 14 · 2014: 4 · 2013: 18 · 2012: 1
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (F32HL104776)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007529)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (K08HD070957)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Eye Disorders
- Keywords
- ipilimumab, bevacizumab, melanoma, CTLA-4 blockade, immune-related adverse events, thyroiditis, Graves' ophthalmopathy, hyperthyroidism, hypothyroidism, TSH receptor antibodies, endocrine disorders, immune checkpoint inhibitors
- MeSH terms
- Ipilimumab, Adult, Antibodies, Monoclonal, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Thyroiditis, Autoimmune, Graves Ophthalmopathy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
